VYNE Therapeutics (VYNE) Income from Continuing Operations (2017 - 2026)
VYNE Therapeutics (VYNE) posted Income from Continuing Operations of 3585000.0 for Q1 2026, up 37.62% on a QoQ basis from 5747000.0 in Q2 2025, and up 58.33% year-over-year from 2264279.79 in Q1 2025.
VYNE Therapeutics (VYNE) Income from Continuing Operations (2017 - 2026) Analysis & Trends
VYNE Therapeutics' Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 3585000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 58.33% year-over-year to 3585000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 29949000.0 (up 28.98% YoY) and the FY2025 annual result came in at 26736000.0, up 32.84% from the prior year.
- Income from Continuing Operations was 3585000.0 for Q1 2026 at VYNE Therapeutics, up from 5747000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 3585000.0 in Q1 2026 and bottomed at 12157000.0 in Q3 2024.
- A 5-year average of 7970666.67 and a median of 8235000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations slumped 100.25% — and 2026, when it jumped 58.33%.
- VYNE Therapeutics' Income from Continuing Operations stood at 7761000.0 in 2022, then climbed by 20.73% to 6152000.0 in 2023, then plunged by 95.29% to 12014000.0 in 2024, then soared by 52.16% to 5747000.0 in 2025, then surged by 37.62% to 3585000.0 in 2026.
- Business Quant data shows VYNE's Income from Continuing Operations at 3585000.0 in Q1 2026, 5747000.0 in Q2 2025, and 8603000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | -3.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.59 Mn |
| Jun 30, 2025 | -5.75 Mn |
| Mar 31, 2025 | -8.60 Mn |
| Dec 31, 2024 | -12.01 Mn |
| Sep 30, 2024 | -12.16 Mn |
| Jun 30, 2024 | -9.40 Mn |
| Mar 31, 2024 | -6.24 Mn |
| Dec 31, 2023 | -6.15 Mn |
| Sep 30, 2023 | -6.07 Mn |
| Jun 30, 2023 | -10.04 Mn |
| Mar 31, 2023 | -5.61 Mn |
| Dec 31, 2022 | -7.76 Mn |
| Sep 30, 2022 | -9.26 Mn |
| Jun 30, 2022 | -8.24 Mn |
| Mar 31, 2022 | -8.69 Mn |
| Dec 31, 2021 | -8.37 Mn |
| Sep 30, 2021 | -14.28 Mn |
| Jun 30, 2021 | -10.69 Mn |
| Mar 31, 2021 | -10.88 Mn |
| Dec 31, 2020 | -23.18 Mn |